Business
Polaryx Announces Key Pre-Clinical Data Related to SOTERIA at the 22nd Annual WORLDSymposium™
Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200
About this update from Polaryx Therapeutics, Inc.
[{"type":"text","content":"Oral presentation highlighted the effect of gemfibrozil on Krabbe disease, one of four LSDs in the upcoming Phase 2 SOTERIA basket trial evaluating PLX-200 (reformulated gemfibrozil)\nPARAMUS, NJ, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announced that the late-breaking presentation of new data for PLX-200, an investigational therapy for the treatment of Krabbe disease (globoid cell leukodystrophy) at the 22nd Annual WORLDSymposium™, was given on February 6, 2026 in San Diego, Calif. Key Findings and Scientific Perspective At the Contemporary Forum, Late-breaking Science and the Rapid Fire Competition, Shrijay Vijayan, Ph.D., MBA, Polaryx Therapeutics’ Chief Scientific and Business Development Officer, presented preclinical findings highlighting that orally administered gemfibrozil in a mouse model of Krabbe disease (GALC-/-): Reduces astrogliosis and neuro-inflammation Protects myelin Reduces psychosine accumulation, a hallmark toxic metabolite found in Krabbe disease patients “Molecular mechanism involved recruitment of proliferator activated receptor beta (PPARβ) to the myelin-specific gene promoters in addition to proliferator activated receptor alpha (PPARα) mediated increase in lysosome biogenesis, autophagy and suppression of neuroinflammation,” noted Dr. Vijayan. “Most importantly, gemfibrozil restored motor functions and increased lifespan in GALC-/-mice.” CEO Perspective “These findings on PLX-200 as a potential novel therapeutic approach for Krabbe disease were encouraging as we prepare for the launch of the SOTERIA trial this year. The data deepen our confidence in the potential to translate PLX‑200’s strong preclinical evidence toward potential benefit for patients and families living with LSDs,” said Alex Yang, Chairman and Chief Executive Officer, Polaryx Therapeutics, Inc. “Along with the data presentation, the Polaryx team, including Dr. Vijayan, Dr. Lisa Bollinger, Polaryx’s Chief Medical Officer, Dr. Minsu Kang, Polaryx’s Director of Regulatory and Clinical Affairs and myself, was delighted to engage with dedicated patient advocacy groups and clinicians who attended WORLDSymposium™ 2026. We were greatly encouraged by the positive feedback r...